ArticleCancer2019

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Karim R Saab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.